Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim

被引：6
|
作者：
Sartori, Roberto [1 ,2 ]
Candiotto, Laura [1 ,2 ]
Ruggeri, Marco [3 ]
Tagariello, Giuseppe [1 ,2 ]
机构：
[1] Castelfranco Veneto Hosp, Haemophilia Ctr, Transfus Serv, I-31033 Castelfranco Veneto, TV, Italy
[2] Castelfranco Veneto Hosp, Dept Haematol, I-31033 Castelfranco Veneto, TV, Italy
[3] San Bortolo Hosp, Dept Cell Therapy & Haematol, Vicenza, Italy
来源：
BLOOD TRANSFUSION | 2014年 / 12卷
关键词：
D O I：
10.2450/2013.0135-13
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S151 / S152
页数：2
相关论文
共 50 条
  • [41] Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
    Tarantino, Michael D.
    Bakshi, Kalpana K.
    Brainsky, Andres
    PLATELETS, 2014, 25 (01) : 55 - 61
  • [42] Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 705 - 713
  • [43] Risk of cataract in primary immune thrombocytopenia adult patients treated with eltrombopag
    Lafaurie, Margaux
    Baricault, Berangere
    Soler, Vincent
    Cassagne, Myriam
    Sailler, Laurent
    Lapeyre-Mestre, Maryse
    Sommet, Agnes
    Moulis, Guillaume
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 601 - 601
  • [44] Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia
    Lambert, Michele P.
    Witmer, Char M.
    Kwiatkowski, Janet L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (06) : E88 - E91
  • [45] A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag
    Wada, Hiroshi
    Sakashita, Takuto
    RESPIRATORY MEDICINE CASE REPORTS, 2020, 31
  • [46] CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG
    Bastida, J.
    Hernandez-Sanchez, J.
    Rodriguez, A.
    Alonso-Lopez, D.
    Lumbreras, E.
    Lopez-Parra, M.
    Bueno, R.
    Veiga, A.
    Hernandez-Rivas, J.
    Gonzalez-Porras, J.
    HAEMATOLOGICA, 2017, 102 : 122 - 122
  • [47] Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study
    Al-Samkari, Hanny
    Jiang, Debbie
    Gernsheimer, Terry B.
    Liebman, Howard A.
    Lee, Susie
    Bernheisel, Chelsea
    Kolodny, Scott
    Wojdyla, Matthew
    Vredenburg, Michael
    Jamieson, Brian
    Cuker, Adam
    BLOOD, 2021, 138
  • [48] Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database
    Fang, Qiongtong
    Huang, Fuqiang
    Liang, Jiabi
    Chen, Yishen
    Li, Cheng
    Zhang, Meirong
    Wu, Xinrong
    Luo, Wenji
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (08) : 707 - 714
  • [49] Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations
    Aoki, T.
    Harada, Y.
    Matsubara, E.
    Suzuki, T.
    Oyama, T.
    Kasai, M.
    Uchida, T.
    Ogura, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 729 - 732
  • [50] A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim
    Tremblay, Gabriel
    Dolph, Mike
    Roy, Anuja
    Neyra, Juliette
    El Ouagari, Khalid
    Forsythe, Anna
    BLOOD, 2017, 130
12345